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Abstract
Background: Studies have shown a correlation between bipolar disorder and diabetes mellitus. It is unclear if this
correlation is a part of common pathophysiological pathways, or if medication for bipolar disorder has negative
effects on blood sugar regulation.
Methods: The Norwegian prescription database was analyzed. Prescriptions for lithium, lamotrigine, carbamazepine
and valproate were used as proxies for bipolar disorder. Prescriptions for insulin and oral anti-diabetic agents were
used as proxies for diabetes mellitus. We explored the association between medication for bipolar disorder and
diabetes medication by logistic regression
Results: We found a strong association between concomitant use of medication to treat diabetes mellitus and
mood stabilizers for the treatment of bipolar disorder. Females had a 30% higher risk compared to men of being
treated for both disorders. Persons using oral anti-diabetic agents had higher odds of receiving valproate than
either lithium or lamotrigine. Use of insulin as monotherapy seemed to have lower odds than oral anti-diabetic
agents of co-prescription of mood stabilizers, compared to the general population.
Conclusions: This study showed a strong association between the use of mood stabilizers and anti-diabetic
agents. The association was stronger among women than men.
Background
The comorbidity between diabetes mellitus and bipolar
disorder has been explored in several studies, with the esti-
mated prevalence varying from about two to five times
higher than in the general population [1-4]. Most studies
have had a small number of participants, and a majority
have investigated the comorbidity in hospitalized patients,
where selection bias may color the results. Few studies
have examined whole population samples and no studies,
to our knowledge, have looked at gender differences with
regard to comorbidity between bipolar disorder and dia-
betes mellitus. The European Psychiatric Association
emphasizes the need to focus on diabetic comorbidity in
patients with severe mental illness [5].
In this cross-sectional study, the Norwegian prescrip-
tion database (NorPD), which encompassed prescriptions
from the total Norwegian population in 2006, was ana-
lyzed. Using prescriptions as a proxy for clinical diag-
noses we aimed to (I) investigate the comorbidity
between diabetes mellitus and bipolar disorder, (II)
explore the effect of gender, (III) look at differences
between insulin and non-insulin dependent diabetes, and
(IV) between different mood stabilizing drugs.
Methods
Data from the NorPD for 2006 were explored. NorPD
contains information on all prescribed drugs, reimbursed
or not, dispensed at pharmacies to individual patients trea-
ted in ambulatory care. Data on use in institutionalized
patients in nursing homes and hospitals are also collected,
but these figures are only registered at an institutional
level. Therefore, drugs dispensed in institutions are not
included in our study. All drugs for chronic diseases in
Norway are covered by the public health care system. This
method is extensively described in articles analyzing data
from the database [6-9]. The medications, which were the
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object of analysis in this study, were mood stabilizers for
the treatment of bipolar disorder, and insulin and oral
anti-diabetic agents for the treatment of diabetes mellitus.
The data were analyzed to ascertain co-prescription of
treatments for bipolar disorder and diabetes mellitus.
Measurements
The medications are grouped according to the Anatomi-
cal Therapeutic Chemical (ATC) classification. We
included patients with prescriptions for N03AG01
(valproate), N03AX09 (lamotrigine), N03AF01 (carbama-
zepine), N05AN01 (lithium), A10A (insulin and insulin
analogues) and A10B (oral anti-diabetics) (Table 1). In
the analyses we have also included antipsychotic medi-
cation as a possible confounder and stratifier. Chlorpro-
mazine (N05AA01), levomepromazine (N05AA02),
perphenazine (N05AB03), prochlorperazine (N05AB04),
haloperidol (N05AD01), flupenthixsol (N05AF01), chlor-
prothixene (N05AF03) and zuclopenthixol (N05AF05)
were catagorized as first generation antipsychotic medi-
cations. Sertindole (N05AE03), ziprasidone (N05AE04),
clozapine (N05AH02), olanzapine (N05AH03), quetia-
pine (N05AH04), risperidone (N05AX08) and aripipra-
zole (N05AX12) were categorized as second generation
antipsychotics. In this study, only valproate, lamotrigine
and carbamazepine used as medication for bipolar disor-
der are included, excluding those people using these
medications that were coded as being for the treatment
of epilepsy. This information is included in the dataset.
Statistical analyses
While the data file obtained from the prescription data-
base included the total Norwegian population of 2006, we
chose to only include persons aged 20 to 69 years (n =
2,929,065, males n = 1,480,648 and females n = 1,448,417).
Odds ratios (OR) and 95% confidence intervals (CI) were
obtained from binary logistic regression to explore the
association between the types of prescriptions. Odds ratios
were used as approximations of relative risk. All analyses
were performed using the Statistical Package for Social
Sciences (SPSS) version 19.0 (IBM SPSS Statistics 19,
SPSS inc., an IBM Co., Somers, NY, USA).
Ethical approval
The patients in the prescription database had an
encrypted unique individual identity-number. Because of
this, no regional ethics committee (IRB) approval was
required for this study.
Results
In 2006, a total of 77,669 persons between the ages of 20
and 69 received either an oral anti-diabetic agent (Table 1),
insulin or both in Norway (2.7% of the population). Insulin
as a monotherapy for diabetes mellitus was received by
22,004 (0.8%) persons, and oral anti-diabetic agents as
monotherapy were received by 45,664 (1.6%) persons. A
total of 10,001 (0.3%) used both insulin and oral anti-
diabetics agents. Treatment for bipolar disorder (valproate,
lithium, carbamazepine or lamotrigine) was received by
17,007 persons (0.6%). Males more frequently received
treatment for diabetes mellitus than females (males = 3.0%,
females = 2.3%), while for bipolar disorder females more
frequently received treatment (males = 0.5%, females =
0.7%). The proportion of persons receiving prescriptions
increased substantially with age for oral anti-diabetic
agents, while a lower proportional increase was observed
for insulin.
A total of 900 persons who received treatment for bipo-
lar disorder also received treatment for diabetes mellitus,
this is 2.1 (CI 95%: 1.9, 2.2) times more frequent than the
rest of the population. Adjusting for sex and age, the odds
ratio was 2.0 (CI 95%: 1.8, 2.1). The odds for persons
receiving insulin in monotherapy to also receive treatment
for bipolar disorder was 1.7 (CI 95%: 1.5, 2.0) times higher
than in the general population. Persons receiving oral anti-
diabetic agents in monotherapy had an odds ratio for also









Bipolar disorder 17,007 0.6
N03AG01 Valproate 3,728 0.1
N03AX09 Lamotrigine 6,501 0.2
N03AF01 Carbamazepine 2,049 0.1
N05AN01 Lithium 6,538 0.2
Diabetes mellitus 77,669 2.7






The drugs are categorized by both their ATC number and their chemical therapeutical name. The number of persons receiving the medications, are aged 20 to
69.
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receiving bipolar medication that was 2.2 (CI 95%: 2.0, 2.3)
times higher than in the general population.
When adjusting for the use of antipsychotic medica-
tions as a possible confounder, the odds for receiving
mood stabilizers and medication for diabetes mellitus
was 1.3 (CI 95%: 1.2, 1.4), adjusted for age and gender.
Excluding all persons receiving antipsychotic medica-
tion, both first and second generation, the odds for
receiving medication for diabetes mellitus and bipolar
disorder was 1.6 (CI 95%: 1.4, 1.7) compared to the gen-
eral population, adjusted for gender and age.
In Table 2, the odds of receiving at least one of the
mood stabilizers for persons using insulin or oral anti-dia-
betic agents was compared to the odds for the rest of the
population. The OR was higher in females than in males
for all combinations. Females had an OR of 1.3 (1.3, 1.4)
compared to men of being treated with both mood stabili-
zers and anti-diabetic drugs, compared to the general
population.
There were some differences in OR between the drugs
used in treatment for bipolar disorder, as seen in Table 2.
Persons receiving oral anti-diabetic agents in monotherapy
had an odds ratio of also receiving valproate combined or
in monotherapy that was 2.6 (CI 95%: 2.2, 3.1) times
higher than in the remainder of the population. This was
significantly different from the odds for lamotrigine com-
bined or in monotherapy and oral anti-diabetic agents in
monotherapy, OR: 1.6 (CI 95%: 1.3, 1.9), and lithium and
oral anti-diabetics, OR: 1.9 (1.7, 2.2), both compared to
the remainder of the population.
Discussion
Our main findings were: (I) a strong association between
use of medication to treat diabetes mellitus and mood sta-
bilizers for the treatment for bipolar disorder, and (II)
females had a 30% higher risk compared to men of being
treated simultaneously for both disorders. We also found
(III) that persons using oral anti-diabetic agents had higher
odds of receiving valproate than either lithium or lamotri-
gine. (IV) Persons receiving insulin in monotherapy
seemed to have a lower odds ratio than persons receiving
oral anti-diabetic agents of also receiving mood stabilizers,
compared to the general population.
Matching results
The present findings are in agreement with previous stu-
dies showing comorbidity between diabetes mellitus and
bipolar disorder. Two studies have shown a prevalence of
diabetes mellitus of 10% in a group of hospitalized bipolar
patients [1,2]. A study [3] found a 26% prevalence of type
II diabetes among patients with bipolar 1 disorder.
Another study reported [10] a 11.7% prevalence of dia-
betes in the bipolar population, and that patients with
comorbid diabetes mellitus and bipolar disorder had a
81% disability rate, compared to 30% in the non-diabetic
bipolar population. None of the studies noted whether this
comorbidity differed by gender, or if the patients were
affected by medication use. Carney [11] investigated medi-
cal comorbidity in women and men with bipolar disorder.
They found diabetes with complications to occur at
increased odds (adjusted OR = 1.54) among 3,557 subjects
with bipolar disorder, compared to the non-bipolar
patients in the sample group. However, the odds of having
uncomplicated diabetes was not significantly elevated
compared to the control population. This finding may be
related to the fact that individuals with psychiatric disor-
ders tend to get poorer and more sporadic medical treat-
ment than the general population. Carney et al. found that
more woman (61%) than men (39%) were identified with
bipolar disorder. However, they did not investigate
whether comorbidity of bipolar disorder and diabetes mel-
litus was different for males and females. Fiedorowicz [4]
found a higher prevalence of diabetes (30%) in 217 bipolar
patients, compared to the general population (12.5%). In a
small sample (women n = 25, men = 18), they found men
to have a higher prevalence of diabetes mellitus (33%)
Table 2 Odds ratios for co-prescription of anti-diabetes agents and mood stabilizers.
Total
Male Female
Drugs OR CI (95%) OR CI (95%) OR Cl (95%)
Lamotrigine and insulin 1.8 (1.3, 2.5) 1.8 (1.3, 2.4) 1.7 (1.3, 2.1)
Carbamazepine and insulin 2.0 (1.3, 3.2) 3.0 (1.9, 4.8) 2.4 (1.8, 3.4)
Lithium and insulin 1.4 (1.0, 1.9) 1.6 (1.1, 2.2) 1.4 (1.1, 1.8)
Valproate and insulin 1.6 (1.1, 2.3) 2.6 (1.8, 3.7) 2.0 (1.5, 2.6)
Lamotrigine and oral antidiabetics 1.3 (1.0, 1.7) 1.8 (1.5, 2.3) 1.6 (1.3, 1.9)
Carbamazepine and oral antidiabetics 1.8 (1.3, 2.5) 2.6 (1.8, 3.6) 2.1 (1.7, 2.7)
Lithium and oral antidiabetics 1.5 (1.2, 1.8) 2.6 (2.2, 3.0) 1.9 (1.7, 2.2)
Valproate and oral antidiabetics 2.4 (1.9, 3.0) 3.0 (2.3, 3.7) 2.6 (2.2, 3.1)
Odds ratios, with 95% CI, for using different mood stabilizers, combined or in in monotherapy for persons using anti-diabetes agents in monotherapy compared
to the non diabetic population (divided into genders).
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than women (28%), but found no significant association
between medication use and cardiovascular risk factors.
Conflicting results
Kessing et al. [12] investigated whether some of the co-
morbidity between diabetes and bipolar disorder could be
the result of conditional probability, or Berkson’s bias.
Patients with osteoarthritis were compared to patients
with bipolar disorder. They found a slightly increased rate
of diabetes among people with bipolar disorder compared
to those with osteoarthritis (aged between 45 and 80
years). However, the prevalence of diabetes mellitus may
have been underestimated and the control group of
osteoarthritis is not ideal [13], due to a not yet understood
association between osteoarthritis and insulin [14-16]. For
example, osteoarthritis and diabetes share an etiological
role of inflammatory pathways, as do mood disorders [17].
Possible mechanisms
Three of the four mood stabilizers analyzed in the present
study (carbamazepine, valproate and lithium) all have the
potential to increase weight and, therefore, may increase
the risk of diabetes type II. Mood stabilizers may also
increase risk of diabetes mellitus in other ways than weight
gain. Insulin tends to be used more for type I diabetes, and
oral hypoglycemic agents more for type II diabetes, and
the linkage between diabetes and bipolar disorder is stron-
ger for type II than for type I diabetes. Valproate and
lithium both inhibit glycogen synthase kinase 3b [18,19],
as does insulin.
The finding of the high diabetes prevalence in patients
with bipolar disorder could indicate that those with this
disorder are at higher risk for diabetes by virtue of a
shared pathophysiology common to both disorders, such
as inflammation [20,21]. There is a genetic risk factor in
both diabetes mellitus and bipolar disorder [22,23].
Women tend to experience more side effects from bipo-
lar treatment [24], particularly weight gain, which may be
a factor explaining the increased OR we found in women
compared to men.
Strengths and limitations
The results are based on data from the total Norwegian
population, and the risk of selection bias is low. Our sam-
ple was initially large; however, only 900 persons received
medication for both bipolar disorder and diabetes mellitus.
This number is nevertheless higher than in any other
study we know. The lack of inclusion of data from hospita-
lized and institutionalized patients probably represents a
small number, as few patients stay in the hospital through-
out an entire year and the majority of the institutionalized
patients are 70 years and older in nursing homes. Mood
stabilizers are used less frequently by persons younger
than 20 and were, therefore, excluded. Treatment with
insulin is not indicated for any other disease than diabetes
mellitus. Persons at risk for developing diabetes mellitus
type II rarely use oral anti-diabetic agents. In Norway,
metformin is rarely used prophylactically in psychiatric
patients. Lithium is to some extent also used for treatment
of unipolar depressed patients; excluding persons on anti-
depressants did not substantially change the OR.
Mood stabilizers might be used by patients diagnosed
with other psychiatric diagnoses, such as schizophrenia,
and this presents a possible confounder, as the preva-
lence of diabetes is increased in patients with schizophre-
nia [25]. We are not aware of data from Norway on the
use of mood stabilizers in schizophrenia, and data from
other countries vary widely [26,27] so it is difficult to
know how important this confounder may be. Of prob-
able greater importance is the ability of antipsychotics to
induce diabetes [28]. However, when adjusting for the
use of antipsychotics the odds of receiving medication for
bipolar disorder and diabetes mellitus was still signifi-
cantly elevated (1.3). When excluding all persons using
any antipsychotic agents, the odds increased to 1.6. Anti-
psychotic medication can possibly account for some of
the correlations we found, but not all. Ruzikova [10]
found that patients with bipolar disorder had a greater
chance of complicated diabetes mellitus. It is therefore
possible that patients with severe bipolar disorder, receiv-
ing both mood stabilizers and antipsychotic treatment,
may have a higher risk of also receiving medication for
diabetes mellitus. This needs to be investigated further.
The prescription database indirectly measures the fre-
quency of diabetes and bipolar disorder in the adult
population, and our risk estimates may, therefore, be
interpreted as a proxy of comorbidity between the dis-
eases. The validity of this measure is likely high, as all
registered prescriptions are based on a physician’s exam-
ination, diagnostic decision, as well as the fact that the
patients have collected their medication. The study does
not include persons who either do not seek treatment,
recognize their illness or for any other reason do not
collect their medication. As such, the study may have
under-estimated the true prevalence and, thus, comor-
bidity. The cost for medical treatment is to a large
extent covered by the public health care system in Nor-
way, and very few persons will fail to purchase medica-
tion for economic reasons.
Conclusions
This study has demonstrated a significant co-prescrip-
tion of drugs used to treat diabetes and bipolar disorder,
which may reflect shared risk pathways, as well as a pos-
sible role of treatment. This has implications for both
the understanding of neurobiology and management.
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